Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia

Alzheimer's Disease Clinical Trial

Official title: Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down Syndrome and Dementia

Status Recruiting

Clinical Trial Summary

The purpose of this study is to develop small molecule radio-labeled probes of beta-amyloid, to be used with positron emission tomography (PET) for early detection and treatment monitoring of Alzheimer disease (AD). The study hypothesis is that PET imaging of small molecule probes, in the form of novel fluorescent dyes with radioactive labels, will demonstrate cerebral patterns in patients with AD that are distinct from those of age-matched persons who are cognitively intact.

Clinical Trial Description

This is a naturalistic study in which clinical evaluations and brain scans will be performed on 72 people with Down syndrome (DS), 36 non-demented and 36 with dementia, as well as 36 age-matched healthy controls. Participants will receive comprehensive clinical and neuropsychological assessments. PET and MRI scans will be performed at baseline and after two years of follow up. All participants will have blood drawn for APOE genotyping during their baseline evaluations. The intellectual range of participants with DS will be restricted to IQ scores of 45 to 60 (moderate range) to reduce variability, particularly due to extreme low levels of intellectual ability. ;

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Down Syndrome
• Syndrome

• NCT number: NCT00966017
• Study type: Observational
• Source: National Institute on Aging (NIA)
• Contact: Andrea Kaplan
• Phone: 310-825-0545
• Email: akaplan@mednet.ucla.edu
• Status: Recruiting
• Phase: N/A
• Start date: July 2009
• Completion date: February 2014